IDEXX Laboratories stock fell 2.21 percent on October 6

Published on 10/07/2026 at 05:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Six of 10 analysts rate the shares Buy, while the average 12-month target is USD 747. Q2 revenue rose 9.7 percent year over year to USD 1.22 billion.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories (ISIN US45168D1046) fell 2.21 percent to USD 515.41 on Nasdaq on October 6, 2026, while its market capitalization stood at USD 40.7 billion. The company has scheduled its third-quarter 2026 results for November 2, 2026, before the market opens, according to IDEXX Laboratories in a release dated October 1, 2026.

November results set the next test

The November 2 release will give investors the next operating checkpoint after a strong second quarter. IDEXX reported USD 1.217 billion in Q2 2026 revenue, up 10 percent year over year, according to Business Wire. The finance statement for the quarter shows diluted EPS of USD 4.27 and an operating margin of 35 percent.

The Q2 EPS result exceeded the USD 3.94 consensus by USD 0.33, while revenue topped the USD 1.20 billion estimate by USD 0.017 billion, according to MarketBeat. The comparison matters because the company enters the November report with fiscal 2026 adjusted EPS guidance of USD 14.69 to USD 14.94.

Consensus remains above the share price

MarketBeat records a Moderate Buy consensus from 10 analysts, with six Buy ratings and four Hold ratings. The average 12-month price target is USD 747.00, which lies 44.9 percent above the October 6 price of USD 515.41.

Recent target changes show a divided valuation debate. UBS raised its target from USD 620.00 to USD 670.00 and Citigroup lifted its target from USD 650.00 to USD 670.00, while Barclays reduced its target from USD 800.00 to USD 710.00, all as reported by MarketBeat. The spread between the targets and the consensus indicates that the November figures will be judged against both growth delivery and valuation.

IDEXX Laboratories stock stays above its yearly low

IDEXX Laboratories stock was last at USD 515.41 on October 6, 2026, at 4:00 p.m. ET. The price remained USD 14.80, or 2.96 percent, above the 52-week low of USD 500.61 and USD 254.57, or 33.06 percent, below the 52-week high of USD 769.98.